Cross‐Neutralization Responses and Persistent Symptoms After SARS‐CoV‐2 Breakthrough Infections
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.71153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Ting Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, SARS-CoV-2, COVID-19. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, Strategic Priority Research Program of the Chinese Academy of Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
The rapid succession of Omicron sub‐variant waves has generated a complex and evolving humoral immune landscape in previously infected populations. To characterize the post‐COVID‐19 humoral immune landscape in China, we conducted a cross‐sectional study evaluating cross‐neutralizing antibody profile and associated epidemiological factors in a Chinese cohort. Serum samples and epidemiological questionnaire data were collected from 273 convalescent volunteers. SARS‐CoV‐2 infection history, vaccination background, and persistent symptoms were obtained via structured surveys. Serum neutralizing antibody (NAb) titers were measured against pseudoviruses representing B.1, BA.2, BA.5, XBB.1.16, JN.1, and KP.3.1.1. Associations of infection frequency, vaccination status, and epidemic era on NAb responses were evaluated. Persistent symptoms lasting ≥ 30 days were reported by 58.97% of participants, most commonly fatigue/malaise (32.60%) and chronic cough (23.08%). NAb titers remained high against B.1, BA.2, and BA.5, a marked 5‐ to 27‐fold reduction was observed against XBB.1.16, JN.1, and KP.3.1.1. Neutralization against KP.3.1.1 showed the greatest reduction, with 42.90% of serum samples below the lower limit of detection. Compared with individuals with one infection, those with repeated infections showed relatively higher titers against later Omicron sub‐variants, particularly XBB.1.16, JN.1, and KP.3.1.1, whereas neutralization against earlier variants was not consistently increased neutralizing profiles also varied by epidemic era of infection, although some subgroup analyzes were limited by small sample sizes. Together, these findings define the cross‐NAb landscape in a real‐world Chinese population after a 3‐year zero‐COVID strategy. Despite modest broadening of humoral immunity following multiple exposures, antigenic divergence of emerging Omicron sub‐variants continues to limit cross‐protection, supporting the need for variant‐adapted vaccination strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
- Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Institute of Pediatrics, Shenzhen Children's Hospital, Shenzhen, China.
- Innovative Vaccine and Immunotherapy Research Center, the Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
- Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
ORCID-Profile: George F Gao
Förderung
- National Key Research and Development Program of China
- Strategic Priority Research Program of the Chinese Academy of Sciences
- National Natural Science Foundation of China
- CAS Project for Young Scientists in Basic Research
- Beijing Life Science Academy
- Beijing Nova Program
- National Basic Research Program of China
Zitieren
APA
Yang, T., Zhang, R., Qin, S., Zheng, Y., Gao, P., Jiang, J., Si, J., Li, D., Zhao, X., & Gao, G. F. (2026). Cross‐Neutralization Responses and Persistent Symptoms After SARS‐CoV‐2 Breakthrough Infections. Journal of Medical Virology. https://doi.org/10.1002/jmv.71153
Vancouver
Yang T, Zhang R, Qin S, Zheng Y, Gao P, Jiang J, et al. Cross‐Neutralization Responses and Persistent Symptoms After SARS‐CoV‐2 Breakthrough Infections. Journal of Medical Virology. 2026. doi:10.1002/jmv.71153
BibTeX
@article{Yang2026,
author = {Yang, Ting and Zhang, Rong and Qin, Shijie and Zheng, Yaqi and Gao, Pengyue and Jiang, Junlan and Si, Jiahui and Li, Dedong and Zhao, Xin and Gao, George F},
title = {Cross‐Neutralization Responses and Persistent Symptoms After SARS‐CoV‐2 Breakthrough Infections},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.71153}
}
EUVIMED